Arterial Stiffness and Calcifications in Haemodialysis Patients on Sevelamer or Calcium Acetate
Haemodialyzed Patients, Hyperphosphatemia
About this trial
This is an interventional treatment trial for Haemodialyzed Patients focused on measuring haemodialysis, hyperphosphatemia, sevelamer, calcium acetate
Eligibility Criteria
Inclusion Criteria: more than 3 months on haemodialysis willingness to participate age 18-60 yrs pre-dialysis blood pressure 120-160 mmHg in the last month prior to the initiation of study or recent (<1 Mo) addition of a new antihypertensive drug iPTH at entry 200-800 pg/mL (as per severe hyperparathyroidism) serum calcium at entry 2.2-2.6 mmol/L Exclusion Criteria: haemodynamic instability uncontrolled hypertension any severe, debilitating disease associated with a reduced survival any major cardiovascular event in the last 12 month before study cinacalcet therapy before study entrance history of parathyroidectomy documented history of poor compliance serious gastrointestinal disease
Sites / Locations
- "Dr Carol Davila" Teaching Hospital of Nephrology
- "CI Parhon" Clinical Hospital
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
I
II
Calcium acetate 670 mg tablets
label sevelamer (RenagelR) 800 mg tablets